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Transforming growth factor-beta (TGF-b) sup-
presses T cell function to maintain self-tolerance
and to promote tumor immune evasion. Yet how
Smad4, a transcription factor component of TGF-b
signaling, regulates T cell function remains unclear.
Here we have demonstrated an essential role for
Smad4 in promoting T cell function during autoim-
munity and anti-tumor immunity. Smad4 deletion
rescued the lethal autoimmunity resulting from
transforming growth factor-beta receptor (TGF-bR)
deletion and compromised T-cell-mediated tumor
rejection. Although Smad4 was dispensable for
T cell generation, homeostasis, and effector function,
it was essential for T cell proliferation after activation
in vitro and in vivo. The transcription factor Myc was
identified to mediate Smad4-controlled T cell prolif-
eration. This study thus reveals a requirement of
Smad4 for T-cell-mediated autoimmunity and tumor
rejection, which is beyond the current paradigm. It
highlights a TGF-bR-independent role for Smad4 in
promoting T cell function, autoimmunity, and anti-
tumor immunity.
INTRODUCTION
Transforming growth factor-beta (TGF-b) is important to main-
tain immune homeostasis and self-tolerance (Li et al., 2006b)
and to promote tumorigenesis by inhibiting tumor immune sur-
veillance (Wahl et al., 2006; Yang et al., 2010). Deletion of TGF-
b1 leads to multifocal autoimmune disease (Shull et al., 1992),
which underscores its essential role in suppressing immune
cell function. As a pleiotropic cytokine, TGF-b regulates various
immune cell types including CD4+ and CD8+ T cells, natural killer
cells, CD8aa+ T cells, B cells, and myeloid cells to control immu-
nity (Cazac and Roes, 2000; Fridlender et al., 2009; Konkel et al.,
2011; Laouar et al., 2005; Li et al., 2006a; Liu et al., 2008; Marie
et al., 2005; Yang et al., 2008a). T cells are the critical target of68 Immunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc.TGF-b, as shown by the fact that disruption of TGF-b signaling
specifically in T cells results in early lethal autoimmunity similar
to what was observed in germline TGF-b1-deficient mice (Li
et al., 2006b; Liu et al., 2008; Marie et al., 2006). In addition,
defective TGF-b signaling in T cells leads to enhanced tumor
rejection (Gorelik and Flavell, 2001). TGF-b controls T cell
response through several mechanisms. It suppresses T cell
proliferation and effector T cell function (Li et al., 2006b), and
additionally promotes the generation, maintenance, and function
of Foxp3-expressing regulatory T (Treg) cells that potently sup-
press immune response (Rubtsov and Rudensky, 2007). In the
absence of TGF-b receptor (TGF-bR), T cells proliferate aber-
rantly in response to self-antigen (Zhang and Bevan, 2012).
Such uncontrolled proliferation leads to uninhibited T helper 1
(Th1) cell-associated responses. The overwhelming Th1 cell
cytokine production impairs Treg cell function to further enhance
inflammatory response, culminating in a systemic inflammation
syndrome and lethal autoimmunity (Ishigame et al., 2013).
Impaired TGF-b signaling contributes to inflammatory diseases
and autoimmunity. Aberrantly enhanced TGF-b signaling in the
tumor microenvironment thwarts immune surveillance and pro-
motes cancer development. Therefore, in order to understand
the etiology of autoimmunity and cancer and to devise effective
therapies against these diseases, it is important to reveal how
TGF-b functions in immune cells, especially in T cells.
TGF-b-activated pathways have been well characterized in
non-T cells (Shi and Massague´, 2003). TGF-b signaling is pre-
dominantly mediated by a Smad transcription-factor-dependent
pathway. Upon ligand binding, TGF-bR phosphorylates and
activates receptor-associated Smad2 and Smad3, which subse-
quently associate with a co-Smad, Smad4, to control target
gene expression (Attisano and Wrana, 2002; Massague´, 1998).
Mitogen-activated protein kinases (MAPKs), including TGF-
b-activated kinase 1 (TAK1), also mediate TGF-b signaling inde-
pendent of Smad proteins (Derynck and Zhang, 2003). Although
the importance of TGF-b in controlling T cell function has been
recognized for two decades, it has not been until recent years
that studies began to delineate the contributions of Smad-
dependent and -independent pathways to T cell function. Con-
forming to the paradigm established in non-T cells, Smad2 and
Smad3 are redundantly required for TGF-b-suppressed T cell
proliferation and Th cell differentiation and for TGF-b-promoted
Treg cell generation (Gu et al., 2012; Takimoto et al., 2010). How-
ever, TAK1 contributes to the homeostasis of thymic-derived
Treg cells (Gu et al., 2012). Nevertheless, how Smad4 controls
T cell function remains unclear.
Based on the current understanding of TGF-b signaling, one
would predict that T-cell-specific deletion of Smad4, a co-
Smad protein central for TGF-b signaling in non-T cells, would
ablate TGF-b signaling in T cells and phenotypically resemble
T-cell-specific TGF-bR-deficient mice (Li et al., 2006b; Liu
et al., 2008;Marie et al., 2006).However,micewith T-cell-specific
deletion ofSmad4aregrossly normalwithout apparent T cell acti-
vation (Yang et al., 2008b). In addition, when these mice are on a
specific genetic background, they spontaneously develop can-
cer but not autoimmunity (Hahn et al., 2011; Kim et al., 2006).
Similarly, people with germline mutations of Smad4 predispose
to familial juvenile polyposis and gastrointestinal cancers
(Howe et al., 1998; Miyaki and Kuroki, 2003) but not autoimmune
disease. These findings question the relationship between
Smad4 and TGF-b signaling in T cells according to established
notions. At least two possible explanations might account for
these observations. One is that other co-regulator(s) for Smad2
and Smad3, such as TIF1g (He et al., 2006), might compensate
for the loss of Smad4 in T cells and that Smad4 is dispensable
for T cell function. The other is that while being involved in TGF-
b-mediated suppression of T cell function, Smad4 also plays a
critical role in promoting T cell function and the loss of Smad4
impairs T cell function to offset the effects of TGF-bR deficiency.
Via genetic models, we provide evidence to support the latter
explanation and reveal an essential role for Smad4 in T cell
function during autoimmunity and tumor immunity.
RESULTS
Smad4 Deletion Rescues Lethal Autoimmunity
Resulting from TGF-bR Deficiency
To address whether Smad4 is dispensable for TGF-b signaling
or has previously unappreciated function to counter-balance
TGF-b-dependent function in T cells, we generated T-cell-spe-
cific Tgfbr2/Smad4/ mice in which T cells were deficient
in both TGF-bRII and Smad4 by crossing Cd4-cre mice (Lee
et al., 2001) with Tgfbr2fl/fl and Smad4fl/fl mice (Chu et al.,
2004; Chytil et al., 2002). If Smad4 is dispensable for T cell func-
tion, one would predict that T-cell-specific Tgfbr2/Smad4/
mice would develop early lethal autoimmunity as in Cd4-cre-
Tgfbr2fl/fl mice (Li et al., 2006a; Marie et al., 2006). However, if
Smad4 plays a role in counter-balancing TGF-b-dependent
function, one would predict that Smad4 deletion would amelio-
rate the lethal autoimmunity inCd4-cre-Tgfbr2fl/fl mice to display
a phenotype similar to Cd4-cre-Smad4fl/fl mice. We found that,
unlike Cd4-cre-Tgfbr2fl/fl mice that succumbed to a systemic,
lympho-proliferative, autoimmune syndrome by 4 weeks after
birth, T-cell-specific Tgfbr2/Smad4/ mice survived well
beyond 4 months of age (Figure 1A). Whereas Cd4-cre-Tgfbr2fl/fl
mice were runted, T-cell-specific Tgfbr2/Smad4/mice were
similar in size to wild-type littermates (data not shown). Smad4
deletion in T cells therefore rescues early lethality of Cd4-cre-
Tgfbr2fl/fl mice.
Abrogation of TGF-bR in T cells results in perturbed develop-
ment of thymocytes (Li et al., 2006a) and spontaneous activationof peripheral T cells (Li et al., 2006a; Marie et al., 2006). We
assessed whether deletion of Smad4 corrected these abnormal-
ities. We first confirmed that Smad4 was efficiently deleted
in Tgfbr2/Smad4/ T cells and that the phosphorylation of
Smad2, a hallmark for the activation of TGF-b signaling, was
abrogated in these T cells (Figure S1A available online). The dis-
tribution of DN, DP, CD4+ SP, and CD8+ SP thymocyte popula-
tions appeared normal in T-cell-specific Tgfbr2/Smad4/
mice (Figure S1B). The expression of CD5, CD24, and CD69
was similar between Tgfbr2/Smad4/ and wild-type thymo-
cytes (Figure S1C). These findings suggest a normal thymocyte
development in T-cell-specific Tgfbr2/Smad4/ mice. In
contrast to the increased lymphocyte numbers found in the pe-
riphery of Cd4-cre-Tgfbr2fl/fl mice, normal numbers of lympho-
cytes were recovered in T-cell-specific Tgfbr2/Smad4/
mice (Figure 1B). Importantly, whereas CD4+ and CD8+ T cells
from Cd4-cre-Tgfbr2fl/fl mice were spontaneously activated
(Figure 1C) and produced large amounts of interferon-g (IFN-g)
(Figure 1D), T cells in T-cell-specific Tgfbr2/Smad4/ mice
maintained a naive state (Figure 1C) with minimal production
of effector cytokine (Figure 1D), similar to wild-type controls.
Smad4 is thus required for the spontaneous T cell activation
due to defective TGF-b signaling in vivo.
Cell-Intrinsic Properties of Tgfbr2–/–Smad4–/– T Cells
Are Normal under Steady State
Because T-cell-extrinsic factors, such as the cytokine milieu
and natural killer T (NKT) cell activation, might influence T cell
phenotypes when TGF-b signal is disrupted (Li et al., 2006a;
Liu et al., 2008; Marie et al., 2006), we investigated whether
Tgfbr2/Smad4/ T cells had cell-intrinsic defects not re-
vealed in T-cell-specific Tgfbr2/Smad4/mice. We mixed
equal numbers of bone marrow cells isolated from wild-type
(CD45.1+) and T-cell-specific Tgfbr2/Smad4/ (CD45.2+)
mice and then transferred them into irradiated recipient mice
deficient in recombination activated gene-1 (Rag1/). In the
mixed bone marrow chimera, Tgfbr2/Smad4/ thymocytes
were generated to a similar extent as their wild-type counter-
parts (Figure 2A) with normal expression of maturation markers
(Figure S2). In addition, the percentages of CD62LloCD44hi
effector T cells were comparable between wild-type and
Tgfbr2/Smad4/ T cells in the same hosts (Figure 2B), sug-
gesting that Tgfbr2/Smad4/ T cells were not spontaneously
activated in the chimeric mice. In agreement with this observa-
tion, the fractions of IFN-g-producing CD4+ Tgfbr2/Smad4/
T cells were similar to that of wild-type counterparts. The
fractions of IFN-g-producing CD8+ Tgfbr2/Smad4/ T cells,
however, were lower than that of wild-type cells (Figure 2C).
Therefore, although TGF-bR-deficient T cells are activated in vivo
in a cell-intrinsic fashion (Li et al., 2006a, and data not shown),
Smad4 deletion corrects such a phenotype of these T cells.
Homeostasis of Tgfbr2–/–Smad4–/– Treg Cells Is
Defective
Impaired generation and function of Treg cells is one of the impor-
tant mechanisms contributing to the lethal autoimmunity and
spontaneous T cell activation in Cd4-cre-Tgfbr2fl/fl mice (Li
et al., 2006a; Marie et al., 2006). We investigated how Treg cells
were affected in T-cell-specific Tgfbr2/Smad4/ mice. UnderImmunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc. 69
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Figure 1. Analysis of Wild-Type, Cd4-cre-Tgfbr2fl/fl, and Cd4-cre-Tgfbr2fl/flSmad4fl/fl Mice
(A) The survival rate of wild-type (WT), Cd4-cre-Tgfbr2fl/fl (RII KO), Cd4-cre-Tgfbr2fl/flSmad4fl/fl (RII-S4 KO) mice at different time after birth.
(B) Total lymphocytes recovered from the peripheral lymph nodes (PLNs), spleens, and thymus of different strains. Means ± SD of five sets of mice are shown;
*p < 0.05.
(C) CD62L and CD44 expression on peripheral T cells in different strains assessed by flow cytometry. Representative results of at least three experiments are
shown.
(D) IFN-g and IL-4 production in peripheral T cells in different strains assessed by flow cytometry. Representative results of at least three experiments (left) and
means ± SD of five sets of mice (right) are shown; *p < 0.05.
See also Figure S1.steady state, similar frequencies and numbers of Foxp3+ Treg
cells were found in T-cell-specific Tgfbr2/Smad4/ and wild-
type mice (Figure 3A). In addition, the suppressive function
of Tgfbr2/Smad4/ Treg cells was comparable to wild-type
Treg cells (Figure 3B). Nonetheless, upon closer examination,
we found that the cell-intrinsic-properties of Tgfbr2/Smad4/
Treg cells were impaired. By creating and analyzing
mixed bone marrow chimeric mice, we found that, although
Tgfbr2/Smad4/ Treg cells weremuchmore efficiently gener-
ated thanTgfbr2/Treg cells in thechimeras (Figure 3C), theper-
centage of Tgfbr2/Smad4/ Treg cells was lower than that of
wild-type counterparts in the same hosts (Figure 3C). In addition,
we investigated how Tgfbr2/Smad4/ Treg cells were main-
tainedunder inflammatory conditions, because IFN-g is important
to disrupt the homeostasis of Treg cells in the absence of TGF-b70 Immunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc.signaling (Ishigame et al., 2013). The non-inflammatory environ-
ment in T-cell-specific Tgfbr2/Smad4/ mice precluded us
fromaddressing this question;we therefore created inflammatory
conditions in vivo by using a T-cell-induced acute graft-versus-
host disease (aGvHD) model. The same numbers of wild-type
(CD45.1+) and Tgfbr2/Smad4/ (CD45.2+) T cells of C57BL/6
background were mixed at a ratio of 1 to 1 and then transferred
into irradiated IL2rg/ mice of BALB/c background to induce
strong inflammatory aGvHD response. Large amounts of IFN-g
were produced by T cells in the recipient mice (data now shown).
Under such condition, the homeostasis of Tgfbr2/Smad4/
Treg cells was greatly impaired when compared to co-existing
wild-type Treg cells (Figure 3D). Collectively, these observations
suggest that deletion of Smad4 is not able to restore normal
Treg cell homeostasis in the absence of TGF-bR.
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Figure 2. Cell-Intrinsic Property of Tgfbr2–/–Smad4–/– T Cells
(A) The percentages of T cells in the peripheral lymph nodes (PLNs), spleens, and thymuses of mixed-bone-marrow-chimeras reconstituted with bone marrow
cells from wild-type (CD45.1+) and Cd4-cre-Tgfbr2fl/flSmad4fl/fl (RII-S4 DKO, CD45.2+) mice, assessed by flow cytometry.
(B) CD62L and CD44 expression on CD4+ (left) and CD8+ (right) T cells ofWT and RII-S4 DKO origins in the chimeras described in (A), assessed by flow cytometry.
(C) IFN-g and IL-4 expression in T cells of WT and RII-S4 DKO origins in the chimeras described in (A), assessed by flow cytometry.
Representative flow cytometry results of at least three experiments (top in each panel) and means ± SD of five sets of mice (bottom in each panel) are shown;
*p < 0.05.
See also Figure S2.The Proliferation of Tgfbr2–/–Smad4–/– T Cells Is
Impaired
The findings described above prompted us to investigate
whether the function of Tgfbr2/Smad4/ non-Treg cells was
impaired. In the absence of TGF-bR, aberrant T cell proliferation
in response to self-antigen and overly exuberant Th1 cell differ-
entiation lead to lethal autoimmunity in mice (Ishigame et al.,
2013; Li et al., 2006b; Marie et al., 2006; Zhang and Bevan,2012). Therefore, aberrant T cell activation and proliferation
and Th cell differentiation are the key elements for uncon-
trolled T cell function in the absence of TGF-b signal.
Tgfbr2/Smad4/ T cells might be defective in these pro-
cesses. Upon T cell receptor (TCR) ligation, Tgfbr2/Smad4/
T cells upregulated the activation markers similarly to wild-
type cells (Figure S3A). Nonetheless, fewer numbers of
Tgfbr2/Smad4/ T cells were recovered compared to thatImmunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc. 71
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Figure 3. Defective Homeostasis of Tgfbr2–/–Smad4–/– Treg Cells
(A) The percentages (left) and absolute numbers (right) of Foxp3+ Treg cells detected in CD4+ T cells in different strains by flow cytometry and live cell counting.
Means ± SD of five sets of mice are shown; *p < 0.05.
(B) Immune-suppressive activity of purified WT and Cd4-cre-Tgfbr2fl/flSmad4fl/fl (RII-S4 DKO) Treg cells (CD4+CD25+) assessed by in vitro suppression assay.
Representative results (left) and means ± SD (right) of three experiments are shown.
(C) The percentages of Foxp3+ Treg cells in CD4+ T cells in the periphery of mixed-bone-marrow chimeras containing both wild-type (CD45.1+) and DKO
(CD45.2+) T cells as in Figure 2 or of chimeras reconstituted with bone marrow cells from wild-type (CD45.1+) and Cd4-cre-Tgfbr2fl/fl (RII KO, CD45.2+) mice,
assessed by flow cytometry. All flow cytometry plots are representative of at least three experiments. All bar graphs are means ± SD of five mice of one
experiment of two; *p < 0.05.
(D) The compositions of Treg cell populations in theRag2–/–Il2rg–/– mice (BALB/c) that have received equal numbers of CD4+ T cells fromwild-typemice (CD45.1+,
C57BL/6) and DKO mice (CD45.2+, C57BL/6). Representative results of at least three experiments (left) and means ± SD of five recipient mice (right) in one
experiment of three are shown; *p < 0.05.of wild-type T cells 3 days after TCR ligation (Figure S3B). Such
a reduction was probably due to impaired proliferation of
Tgfbr2/Smad4/ T cells (Figure 4A), because these T cells72 Immunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc.survived similarly as wild-type T cells (Figure S3C) with compa-
rable expression of the genes controlling cell survival (Fig-
ure S3D). In addition, the cell sizes of Tgfbr2/Smad4/
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Figure 4. Defective Function of Tgfbr2–/–Smad4–/– T Cells
(A) Anti-CD3 and anti-CD28 activated proliferation of T cells isolated from wild-type (WT) and Cd4-cre-Tgfbr2fl/flSmad4fl/fl (RII-S4 DKO) mice assessed by flow
cytometry of CFSE dilution (left). Division index was calculated with FlowJo software (right). Means ± SD of three experiments are shown; *p < 0.05.
(B) T cell sizes assessed by flow cytometry 48 hr after anti-CD3 and anti-CD28 stimulation.
(C) The percentages of T cells in Rag2–/–Il2rg–/– recipient mice (BALB/c) transferred with splenocytes from wild-type (CD45.1+) and Cd4-cre-Tgfbr2fl/flSmad4fl/fl
(RII-S4 DKO, CD45.2+) mice (C57BL/6) assessed by flow cytometry. Representative results (left) and means ± SD of five mice in one experiment of two (right) are
shown.
(D) IFN-g, IL-4, and Foxp3 expression in CD4+ T cells assessed by flow cytometry after being differentiated under Th1, Th2, and iTreg cell-polarizing conditions.
Means ± SD of three experiments are shown.
See also Figure S3.T cells measured by forward-scatter by flow cytometry were
smaller than that of wild-type T cells after being activated
in vitro (Figure 4B), suggesting a defect in the growth of such
T cells. The defective expansion of Tgfbr2/Smad4/ T cell
population could also be observed during a GvHD response
in vivo (Figure 4C), an allo-immune response that shares many
features with autoimmune response (Shlomchik, 2007; Welniak
et al., 2007). Although Tgfbr2/Smad4/ T cells could be
differentiated into Th1 and Th2 cells similarly to wild-type
T cells (Figures 4D and S3E), they failed to differentiate into
Foxp3+ Treg cells in the presence of TGF-b (Figure 4D; Chen
et al., 2003). Lack of TGF-b-induced Treg cell differentiation
agreed with and contributed to the observation that fewer
Tgfbr2/Smad4/ than wild-type Treg cells were recovered
in mixed bone marrow chimeras and during GvHD response
(Figures 3C and 3D). Therefore, Tgfbr2/Smad4/ T cells are
defective in activation-induced proliferation.
Smad4 Is Required for T Cell Function in Inflammation
and Cancer
Aforementioned observations suggest that Smad4 plays an
essential role in promoting T cell function. To test this possibility,
we investigated whether the activation, proliferation, and/or dif-ferentiation of T cells were affected in the absence of Smad4.
Naive T cells isolated from Cd4-cre-Smad4fl/fl mice were acti-
vated normally with efficient upregulation of activation markers
(Figure S4A). Fewer Smad4-deficient than -sufficient T cells
were recovered 3 days after activation (Figure S4B). Although
Smad4-deficient T cells survived similarly as wild-type T cells
(Figure S4C) with comparable expression of genes that control
T cell survival (Figure S4D), the proliferation of Smad4-deficient
T cells was impaired after TCR stimulation in vitro (Figure 5A).
In addition, the sizes of activated Smad4-deficient T cells were
smaller than that of Smad4-sufficient T cells in vitro (Figure 5B),
indicating that activation-induced growth of Smad4-deficient
T cells was impaired. Although Th1 and Th2 cell differentiation
and IL-2 production of Smad4-deficient CD4+ T cells were
largely normal (Figures S4E–S4G), TGF-b-induced Treg cell dif-
ferentiation of these cells was defective (Figure S4E), which is
in agreement with a previous report (Yang et al., 2008b) and sug-
gests that Smad4 indeed mediates TGF-b signaling in T cells.
Similar to Tgfbr2/Smad4/ T cells, Smad4/ T cells
expanded poorly when compared to wild-type cells during a
GvHD response in vivo (Figure 5C). This observation could be
due to impaired proliferation driven by lymphopenic condition
and/or by cognate antigen stimulation. Smad4-deficient T cellsImmunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc. 73
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Figure 5. Smad4 Is Required for T Cell Function
(A) The proliferation of T cells isolated fromwild-type andCd4-cre-Smad4fl/fl (S4 KO) mice assessed as in Figure 4A. Means ± SD of three experiments are shown;
*p < 0.05.
(B) T cell sizes assessed by flow cytometry 48 hr after anti-CD3 and anti-CD28 stimulation. Results are representative of at least three experiments.
(C) The fractions of T cells in Rag2–/–Il2rg–/– recipient mice (BALB/c) that have received splenocytes from wild-type (CD45.1+) and Cd4-cre-Smad4fl/fl (S4 KO,
CD45.2+) mice (C57BL/6) assessed by flow cytometry. Representative flow cytometry results (left) andmeans ± SD of five mice in one experiment representative
of two (right) are shown.
(D) CD4+ and CD8+ T cells were isolated from wild-type (CD45.1+CD45.2+) and Cd4-cre-Smad4fl/fl mice (S4 KO, CD45.2+) mice. Cells of different origins were
mixed and labeled with CFSE and transferred into sublethally irradiated wild-type (CD45.1+) mice. The proliferation of transferred cells in the recipients was
assessed 5 days after transfer. Results are representative of at least three experiments.
(E) CD4+ T cells were isolated fromCd4-cre-Smad4fl/+-OT-II (WTOTII, CD45.1+CD45.2+) andCd4-cre-Smad4fl/fl-OT-II mice (S4 KOOTII, CD45.2+) mice, mixed at
the ratio of 1 to 1, labeled with CFSE, and then transferred into syngeneic wild-type mice (CD45.1+). The proliferation and the numbers of transferred cells of
different origins in the spleens were assessed 60 hr after the recipient mice were injected with different doses of OVA proteins (as indicated). Representative flow
cytometry results of at least three experiments are shown. Means ± SD of the cell numbers are shown; *p < 0.05.
(F) The incidence of tumor development (R3 mm in diameter) in WT OT-II and Cd4-cre-Smad4fl/fl-OT-II (S4 KO OTII) mice inoculated s.c. with OVA-expressing
melanoma cells (20,000 cells/injection). Combined results of three independent experiments are plotted.
See also Figure S4.
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proliferated less thanwild-type T cells when transferred into sub-
lethally irradiated syngeneic recipients, (Figure 5D), suggesting
that Smad4 is required for lymphopenia-driven T cell prolifera-
tion. To test how Smad4 deletion might affect T cell proliferation
in response to cognate antigen, we crossed Cd4-cre-Smad4fl/fl
mice with OT-II TCR transgenic mice to obtain Cd4-cre-
Smad4fl/fl-OT-II T cells that respond specifically to peptide
323–339 of chicken ovalbumin protein (OVA). Compared to co-
transferred wild-type OT-II cells, Smad4-deficient OT-II cells
proliferated less in response to OVA protein stimulation in the
immune-competent syngeneic hosts (Figures 5E and S4H).
Smad4 mutation has been associated with cancers in humans
and mice (Hahn et al., 2011; Howe et al., 1998; Kim et al., 2006;
Miyaki and Kuroki, 2003). The immune etiology is not entirely
clear, although enhanced Th cell responses might contribute to
cancer development (Hahn et al., 2011; Kim et al., 2006). The
finding that Smad4-deficient T cells proliferated poorly after
cognate antigen stimulation suggests that Smad4 might be
required for T-cell-mediated tumor rejection. Indeed, although
the growth of engrafted OVA-expressing B16 melanoma was
controlled effectively in wild-type OT-II TCR transgenic
(Tg) recipient mice, a large percentage of Cd4-cre-Smad4fl/fl-
OT-II mice developed melanoma after tumor cell engraftment
(Figure 5F).
The above-mentioned observations suggest that although
Smad4 is largely dispensable for T cell activation and Th cell dif-
ferentiation, it is required for T cell proliferation in response to
cognate antigen to promote T-cell-mediated inflammatory dis-
ease and tumor rejection.
Myc Transcription Factor Is Important for
Smad4-Controlled T Cell Proliferation
We further investigated the molecular mechanisms underlying
the defective growth and proliferation of activated Smad4-defi-
cient T cells. Because Myc is a central regulator for T cell
growth and proliferation (Nie et al., 2012; Wang et al., 2011)
and Smad4 has been suggested to promote Myc expression
in tumor cells (Lim and Hoffmann, 2006), we hypothesized
that the expression of Myc was dysregulated in Smad4-defi-
cient T cells. Indeed, after activation, Myc expression in
Tgfbr2/Smad4/ and Smad4/ T cells was lower than in
wild-type T cells (Figures 6A and 6B), suggesting that Myc func-
tions downstream of Smad4 to control T cell proliferation.
To test whether Myc downregulation is functionally important
for defective proliferation of Smad4-deficient T cells, we ex-
pressed Myc in activated Smad4-deficient T cells via retro-
virus-mediated gene delivery. Ectopic Myc expression largely
restored the proliferation of Smad4-deficient T cells after activa-
tion in vitro (Figure 6C) as well as in vivo during a GvHD
response (Figures 6D and S5), indicating that Myc is an
important Smad4 downstream target to control T cell prolifera-
tion, although Myc-independent mechanisms might also be
involved. Smad4 might promote Myc expression by binding to
a TGF-b-independent site in the Myc locus in T cells (Lim and
Hoffmann, 2006). By using chromatin immunoprecipitation
(ChIP) assay, we found that Smad4 binding was enriched at
this site in T cells (Figure 6E). Therefore, one of the important
mechanisms by which Smad4 promotes T cell proliferation is
through regulating Myc expression.DISCUSSION
TGF-b suppresses autoimmunity and promotes tumorigenesis
by regulating T cell function. Nonetheless, how Smad4 (a central
component for TGF-b signaling) is involved in T cell function dur-
ing autoimmunity and malignancies is unclear. T-cell-specific
deletion of Smad4 is associated with cancer but not with autoim-
munity (Hahn et al., 2011; Kim et al., 2006). Here, we found that
Smad4 was essential for the proliferation of T cells and Myc
expression. Importantly, deletion of Smad4 in T cells rescued
early lethal autoimmunity in mice whose T cells lack TGF-bR
and led to impaired tumor rejection. These findings therefore
reveal a previously unappreciated requirement of Smad4 to pro-
mote T cell function for autoimmunity and tumor immune surveil-
lance. The information gained from this study sheds light on
TGF-b signaling and Smad function and provides insights into
the control of T cell function, autoimmunity, and cancer.
Aberrant T cell proliferation and uncontrolled T cell activation
and effector function contribute to various types of inflammatory
diseases. Therefore, inhibiting the proliferation and pro-inflam-
matory function of T cells is effective to treat such illness. Current
strategies aiming to interfere with pro-inflammatory T cell func-
tion often lead to the ablation of lymphocyte population and
abrogation of effector T cell function, which could be detrimental
to the patients. It is therefore important to identify pathways that
are essential for autoimmunity development but largely dispens-
able for T cell homeostasis. By studying Cd4-cre-Tgfbr2fl/fl mice
whose T cells lack TGF-b signaling, a pathway frequently
impaired in various autoimmune and inflammatory diseases (Li
et al., 2006b), we found that Smad4 deletion corrected the lethal
autoimmunity in these mice. Although Smad4-deficient T cells
were generated, maintained, activated, and differentiated
normally, their proliferation was impaired. Therefore, one of the
key steps leading to autoimmunity in mice lacking TGF-b
signaling is the aberrant T cell proliferation, which is a prerequi-
site for the uncontrolled T cell activation and differentiation in
these mice as suggested by a previous study (Zhang and Bevan,
2012). More importantly, this observation suggests that
modestly inhibiting T cell proliferation could be sufficient to pre-
vent autoimmunity and that Smad4 might be a promising target
for treating autoimmunity without the drastic measures of
ablating T cell population or function.
Treg cells are critical to maintain self-tolerance and immune
homeostasis. Impaired Treg cell function has been implicated
in nearly every autoimmune and inflammatory disease. It is there-
fore thought that defective Treg cell function will invariantly lead
to inflammatory disorders. We found that although Smad4 dele-
tion rescued the early lethal autoimmune syndrome and restored
naive T cell phenotype in mice whose T cells lacking TGF-bR, the
homeostasis of Tgfbr2/Smad4/ Treg cells was defective
especially under inflammatory conditions. These findings indi-
cate that impaired Treg cell function might not always lead to
inflammation and autoimmunity when the function of conven-
tional T cells is defective to a modest extent.
This study sheds light on the etiology of certain cancers. Peo-
ple with loss-of-function mutation of Smad4 are predisposed to
the development of familial juvenile polyposis and gastric-intes-
tinal cancers at older age (Howe et al., 1998; Miyaki and Kuroki,
2003). The immune etiology of such cancers is not entirely clear.Immunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc. 75
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Although increased Th cell differentiation of Smad4-deficient
T cells is associated with cancer development (Hahn et al.,
2011; Kim et al., 2006), other mechanisms might also contribute.
The current study provides another plausible immune mecha-
nism for the cancer development in people with Smad4 muta-
tion. We found that Smad4-deficient cells proliferated poorly in
response to cognate and tumor antigen and showed reduced
ability to reject engraft tumor cells. Therefore, Smad4 mutation
impairs T-cell-mediated tumor rejection to allow tumor growth.
These new insights might facilitate the development of effective
anti-cancer drugs. Blocking TGF-b signaling has been explored
as an immunotherapy against cancers (Bierie and Moses, 2006;
Yingling et al., 2004). The observation that Smad4-deficient
T cells are functionally defective even when TGF-b signaling is
abrogated suggests that anti-TGF-b signaling immunotherapy
might be tumor type specific and might not be efficacious
when Smad4 function is perturbed.
We found that Smad4-deficient T cells proliferated poorly
compared to wild-type T cells even in the absence of TGF-b
signaling. It suggests that the proliferation of T cells is controlled
by Smad4-dependent, TGF-b-independent pathways. Smad4 is
a hub integrating multiple signaling pathways. Smad4 mediates
the signaling of TGF-b superfamily members including TGF-bs,
bone morphogenetic proteins (BMPs), activins, and growth dif-
ferentiation factors (GDFs) (Massague´ et al., 2005). In addition,
Smad4 is involved in Wnt and Notch signaling (Massague´,
2012). Moreover, Smad4 interacts with critical cell cycle regula-
tors, such as E2Fs, that do not mediate specific upstream
signaling (Taylor and Wrana, 2008). Therefore, Smad4 might
control T cell proliferation through many diverse pathways inde-
pendent of TGF-b. BMP signaling might be involved in this pro-
cess; it has been suggested that BMP signaling is important
for T cell proliferation (Yoshioka et al., 2012). We found that
Smad4 is required for optimalMyc expression in T cells. Previous
studies show that, through a TGF-b-independent mechanism,
Smad4 promotes Myc expression in tumor cells by cooperating
with TCF1 (Lim and Hoffmann, 2006), a factor important to
mediate Notch andWnt signal in T cells (Staal et al., 2008;Weber
et al., 2011). Because Notch andWnt signal promotes cell prolif-
eration (Artavanis-Tsakonas et al., 1999; Staal et al., 2008),
Smad4 might control T cell proliferation also through Notch
and Wnt-TCF1 signal axis. Therefore, Smad4 might promote
T cell function by integrating multiple pathways independent of
TGF-b. The question of what the Smad4-dependent pathways
are and how precisely they contribute to T cell function through
Smad4 in vitro and in vivo is of interest and warrants further
investigation in order to understand the etiology of and devise
therapies against diseases including autoimmunity and cancer.Figure 6. Smad4 Controls T Cell Proliferation through Myc
(A and B) Myc expression in T cells assessed by flow cytometry (left) and immuno
(C) The proliferation of wild-type and Cd4-cre-Smad4fl/fl (S4 KO) CD4+ and CD8+
Myc-IRES-EGFP (MIG-Myc), assessed by flow cytometry of CellTrace violet dilu
(D) The fractions of T cells in Rag2–/–Il2rg–/– recipient mice (BALB/c) received MIG
Cd4-cre-Smad4fl/fl (S4 KO, CD45.2+) mice (C57BL/6) assessed by flow cytometry
three are shown.
(E) ChIP analysis of Smad4 binding to TGF-b-independent elements (TBE) inMyc l
site inMyc locus was used as positive (Pos. Ctrl.) and negative (Neg. Ctrl.) control
shown; *p < 0.05.
See also Figure S5.EXPERIMENTAL PROCEDURES
Mice
Smad4fl/fl, Tgfbr2fl/fl, Cd4-cre, Rag1/, OT-II, and CD45.1 congenic wild-type
mice were on the C57BL/6 background. Rag2–/–Il2rg–/– mice were on the
BALB/c background. All mice were housed and bred in specific-pathogen-
free conditions in the animal facility at the University of North Carolina at
Chapel Hill. All mouse experiments were approved by Institution Animal
Care and Use Committee of the University of North Carolina.
Flow Cytometry and Cell Sorting
Lymphocytes were isolated from the various organs of age- and sex-matched
mice 3–16 weeks of age. Fluorescence-conjugated anti-CD4 (GK1.5), anti-
CD8 (53-6.7), anti-CD5 (53-7.3), anti-CD24 (30-F1), anti-CD25 (PC61.5), anti-
CD44 (IM7), anti-CD69 (H1.2F3), anti-CD62L (MEL-14), anti-CD45.1 (A20),
anti-CD45.2 (104), anti-IFN-g (XMG1.2), anti-IL-4 (11B11), anti-IL-2 (JES6-
5H4), and anti-Foxp3 (FJK-16 s) (eBioscience), Myc (9E10, Santa Cruz), as
well as Annexin V and 7-amino-actinomycin D (BD Biosciences) were used.
For intracellular cytokine staining, lymphocytes were stimulated for 4 hr with
50 ng/ml of PMA (phorbol 12-myristate 13-acetate) and 1 mM ionomycin in
the presence of brefeldin A. Stained cells were analyzed on an LSRII (BD Bio-
sciences) or were sorted on a MoFlo (DakoCytomation; Beckman Coulter).
T Cell Activation, Proliferation, and Differentiation and Treg Cell
Suppression Assay
Naive (CD62LhiCD44lo) T cells were sorted from the peripheral lymph nodes
and/or spleens of mice. Cells were then activated by stimulation via the TCR
by anti-CD3 (145-2C11; BioXCell) and anti-CD28 (37.51; BioXCell). For prolif-
eration assays, cells were labeled with CFSE (carboxyfluorescein diacetate
succinimidyl ester) or CellTrace Violet (BD Biosciences) and then cultured
under the appropriate conditions. Proliferation was assessed by the dilution
of live dye with flow cytometry 72–96 hr after T cell activation. Th1 cells
were differentiated in the presence of 20 ng/ml rIL-12 (R&D Systems) and
20 mg/ml anti-IL-4 (11B11, BioXcell). Th2 cells were differentiated in the
presence of 20 ng/ml rIL-4 (R&D Systems) and 20 mg/ml anti-IFN-g
(XMG1.2, BioXcell). Treg cells were differentiated in the presence of 2 ng/ml
rTGF-b1 (R&D Systems). To assess the efficacy of Treg-cell-mediated immune
suppression in vitro, 2 3 104 sorted CD4+CD25CD45RBhi responder T cells
were labeled with CFSE and mixed with varying amounts (as indicated) of
CD4+CD25+ Treg suppressor cells. Cell mixtures were stimulated with soluble
anti-CD3 antibody (1 mg/ml) in the presence of 1 3 105 irradiated (3,000 cGy)
T-cell-depleted splenocytes as APCs. The proliferation of responder cells was
assessed by CFSE dilution detected by flow cytometry 72 hr after stimulation.
Mixed Bone Marrow Chimeras
Bone marrow cells were isolated from the femur bones of sex- and
age-matched Cd4-cre-Tgfbr2fl/fl (CD45.2+) or Cd4-cre-Tgfbr2fl/flSmad4fl/fl
(CD45.2+) mice and wild-type (CD45.1+) mice. Bone marrow cells (1 3 106)
from each donor were mixed and transferred into sub-lethally irradiated (400
cGy) Rag1/ recipient mice. T cell populations of each donor origin were
determined in the recipients 8–12 weeks after transfer.
Mouse Model of the Graft-versus-Host Response
Total splenocytes from sex- and age-matched Cd4-cre-Tgfbr2fl/flSmad4fl/fl
(CD45.2+) or Cd4-cre-Smad4fl/fl (CD45.2+) mice and wild-type (CD45.1+)blotting (right). Representative results of at least three experiments are shown.
T cells that were transduced (GFP+) with MSCV-IRES-EGFP (MIG) or MSCV-
tion. Results are representative of at least three experiments.
and MIG-Myc transduced (GFP+) CD4+ T cells from wild-type (CD45.1+) and
. Representative results (left) and means ± SD of five mice in one experiment of
ocus in freshly isolated T cells. TGF-b-inhibitory elements (TIE) and an irrelevant
s, respectively. Means ± SD of triplicates in one experiment of at least three are
Immunity 42, 68–79, January 20, 2015 ª2015 Elsevier Inc. 77
mice of C57BL/6 background were mixed at a ratio of 1:1 and then transferred
into sub-lethally irradiated Rag2–/–Il2rg–/– mice on the BALB/c background by
retro-orbital injection. Recipient mice were monitored and euthanized at the
appropriate time. T cells from the spleens of recipient mice were collected
and subjected to immunological analysis.
Immunoblot Analysis
Protein extracts were resolved by 4%–12% SDS-PAGE (Invitrogen), then
were transferred to a polyvinylidene fluoride membrane (Millipore) and
analyzed by immunoblotting with the following antibodies: anti-Smad4
(#9515, Cell Signaling), anti-phospho-Smad2 (D43B4, Cell Signaling), anti-
c-Myc (D84C12; Cell Signaling), and anti-b-actin (I-19; Santa Cruz).
ChIP Assay
The ChIP assay was done according to the protocol of Upstate Biotechnology.
Cells were crosslinked by 1% formaldehyde and were lysed in lysis buffer.
Lysates were sonicated with a Bioruptor sonicator to shear genomic DNA
into fragments. Chromatin prepared from 2 3 106 cells were subjected to
immunoprecipitation overnight at 4C with goat anti-Smad4 (sc-1909; Santa
Cruz) or normal goat immunoglobulin G (sc-2028; Santa Cruz). Quantitative
real-time PCR was done to determine the relative abundance of target DNA.
Specific primers for analysis of the binding of Smad4 to target loci are as
follows: TBE, 50-TGGCATATTCTCGCGTCTAGC-30 and 50-AGGAGTCTCTG
CCGGTCTACA-30; TIE: 50-CTTTATATTCCGGGGGTCTGC-30 and 50-GCAATG
GGCAAAGTTTCCCA-30; negative control: 50-GGGTACATGGCGTATTGTGT-
30 and 50-TCGGCTGAACTGTGTTCTTG-30.
Statistical Analysis
Data from at least three sets of samples were used for statistical analysis.
Statistical significance was calculated by Student’s t test. A p value of less
than 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
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